Drug Profile
ZYL 65987
Alternative Names: ZYL65987Latest Information Update: 23 Jan 2018
Price :
$50
*
At a glance
- Originator Zylera Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 17 Nov 2017 Zylera Pharmaceuticals was acquired by Cerecor as result of the acquisition of TRx pharma
- 28 Dec 2015 Phase-II clinical trials in Undefined indication in USA (unspecified route)
- 26 Apr 2012 ZYL 65987 is available for licensing as of 26 Apr 2012. http://www.zylera.com